Background: The occurrence of autoimmune hemolytic anemia (AIHA) in patients with non-Hodgkin's lymphoma (NHL) is well known. However, there is lack of information in the literature in terms of the significance and impact of such phenomenon on the clinical course of these patients.
Introduction
The association between autoimmune hemolytic anemia (AIHA) and non-Hodgkin's lymphoma (NHL) is well known and has been described in both B-and T-cell NHL [1, 2] , The pathogenesis of AIHA, or for that matter, all autoimmune phenomena complicating the course of NHL remains a matter of considerable controversy [2] [3] [4] [5] [6] .
Most of the available reports in the English-language literature have analyzed the link between NHL and AIHA in the context of other systemic autoimmune disorders [7, 8] . None of the studies, however, have addressed this relation in terms of determining the relevance of certain clinicopathologic information such as cell type (B-vs. T-cell NHL), presence of serum monoclonal immunoglobulin and stage of disease on the occurrence of AIHA. The impact of AIHA as an isolated phenomenon on the survival of patients with NHL has not been studied as well.
We describe the clinical, laboratory and pathologic features of 16 patients with NHL and AIHA and examine the relevance of certain parameters on their response and survival as compared to the total cohort. Also, we provide suggestions on the pathogenic mechanisms implicated in the formation of antibodies against red blood cells (RBCs) in this group of patients.
Patients and methods
Records of patients with NHL presenting to two major medical centers (East Carolina University, Greenville, North Carolina and the University of North Carolina at Chapel Hill, North Carolina, USA) over a 10-year period (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) were examined to identify those with AIHA.
The diagnosis of NHL was based on the examination of lymph node biopsy and the stage was reported according to the Ann Arbor system [9] . AIHA was diagnosed by a positive direct antiglobulin test (DAT), falling hemoglobin, reticulocytosis and increased indirect bilirubin. Patient 10 has been reported previously [10] . Serum protein electrophoresis were available on patients at the time of diagnosis of NHL. Increased concentrations of structurally homogenous protein in the serum was defined as monoclonal protein. The identity of such monoclonal spike (IgG or IgM) was established using electrophoresis and if indicated, immunofixation. If appropriate, follow-up studies were performed to confirm the status of serum immunoglobulin after treatment.
Because of the impact of AIHA on the staging and treatment decisions of patients with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), this group of patients were not included in the analysis [II, 12] . Also, because AIHA is an essential presenting feature of angioimmunoblastic lymphadenopathy with dysproteinemia. these patients were excluded from the study [2, 13] .
After confirmation of the histologic diagnosis, careful history and physical examination were available on all patients. Routine studies including complete blood counts, chemistry profile and chest radiograph and bone marrow biopsies were performed in all patients in this analysis. Imaging studies to investigate the presence of occult involvement were also available on these patients. Further tests were performed as indicated by the results above (e.g., liver biopsy, skin biopsy). All studies that were abnormal before therapy were repeated after two cycles and at the conclusion of treatment. Response of AIHA to treatment was defined as increase in hemoglobin and/or decrease in reticulocyte count, decrease in indirect bilirubin and absence of further requirements for transfusion support. A repeat negative DAT was not considered a criterion for response because of the known variability of this test to become negative after therapy. Complete response (CR) of NHL was defined as disappearance of any evidence of lymphoma upon re-staging studies, while partial response (PR) was considered as at least 50% reduction in the involved areas following treatment.
Statistics
Because time to complete response and time to survival are subject to censoring, Kaplan-Meier method was used followed by log-rank test for two-sample test. In some special cases where the times are not subject to censoring, we used Wilcoxon rank sum test. The chi-squared test was used for categorical data such as the relationship between cell types of NHL and patients with NHL/AIHA and the cohort When the cell sizes were too small, Fisher's exact test was used instead.
Results
Between June 1989 and July 1999, 674 patients with the diagnosis of NHL were identified. Because of the lack of critical information, 157 patients were excluded from the analysis. Of the remaining 517 patients, 16 (3%) were diagnosed with AIHA. None of the patients in the cohort group had DAT negative hemolytic anemia.
Characteristics of patients
The median age of the 4 men and 12 women with NHL/ AIHA was 68 years (range 33-82 years). Table 1 lists the demographics of these patients. Of the 16 patients, 4 had stage II, 2 stage III and 10 stage IV NHL. Based on immunophenotypic studies, 10 patients had B-cell NHL, 5 T-cell NHL and 1 patient had poorly differentiated NHL. The histologic diagnosis for the patients with T-cell disease was as follows: lymphoblastic lymphoma; large cell anaplastic; cutaneous T-cell; y5-T-cell and peripheral T-cell lymphoma. Of the 501 patients representing the cohort (NHL without AIHA), there were 31 patients with stage I, 141 stage II, 37 stage III and 292 stage IV NHL. Immunophenotypic analysis were consistent with B-cell NHL in 408 patients and T-cell NHL in 64 patients, while cell type was undefined in 29 individuals. Autoimmune hemolytic anemia AIHA with warm-reactive antibodies was seen in 13 patients (81%) and AIHA with cold-reactive antibodies in 3 patients. In nine patients, the diagnosis of AIHA preceded that of NHL, while in seven patients, AIHA occurred either at the time of diagnosis of NHL or during the course of the disease. Table 2 depicts critical diagnostic and laboratory findings of patients with NHL and AIHA. The occurrence of AIHA was not significantly different among the four stages of NHL (P -0.722). Patients with NHL and AIHA were more likely to have T-cell NHL when compared to cohort (33% vs. 14%; P = 0.047). A significantly higher proportion of patients with AIHA were females (P -0.005). Table 3 provides comparison of important data between the two groups.
Evans syndrome (AIHA and immune thrombocytopenia) was present in two patients (3 and 16). Both patients had erythroid hyperplasia and increased bone marrow megakaryocytes. Two patients had vasculitis while systemic lupus erythematousus, positive rheumatoid factor and scleroderma were present in one patient each.
Increase in serum IgG was seen in five patients (31%) and monoclonal serum IgM was present in four patients (25%). When compared to cohort, a significantly higher proportion of patients with NHL/AIHA were diagnosed with monoclonal gammopathy (8% vs. 25%; P -0.03). Table 4 depicts treatment characteristics of the patients with NHL/AIHA. The CR was 44% (7 patients) and the PR 37.5% (6 patients). Eight patients were diagnosed Abbreviations: RC -reticulocyte count; BM -bone marrow; FSC -folllicular small cleaved; EH -erythroid hyperplasia; DLC -diffuse large cell; LL -lymphoblastic lymphoma; LCA -large-cell anaplastic; FM -follicular mixed; C-TL -cutaneous T-cell; y5T -y8-T-cell lymphoma; MALT -mucosa associated lymphoid tissue; PD -poorly differentiated; PT-CL -peripheral T-cell lymphoma; C 3 -complement; RF -rheumatoid factor; NA -not applicable.
Response to therapy
with recurrence of their lymphoma; one recurrence was after CR. Although a higher proportion of the cohort achieved CR (62%), this was not statistically significant when compared to the group with AIHA (P = 0.138). Figure 1 depicts Kaplan-Meier estimate for T-CR for the 2 groups (/> = 0.167).
Resolution of AIHA was achieved in 14 patients (87.5%) at a median time of 9 days. Recurrence of AIHA subsequently occurred in six patients. In five of these patients, the recurrence of AIHA coincided with that of NHL, while in one patient (no. 15) it reappeared shortly following splenectomy and during hospitalization for sepsis. Both NHL and AIHA were refractory to chemotherapy in two of the three patients with cold agglutinin disease (patients 9 and 10). The median T-CR for patients who had durable responses and those with recurrence of AIHA was 7.5 d vs. 13 d, respectively; P = 0.04.
Survival
Of the 16 patients with NHL/AIHA, 7 patients were still alive at the time of this analysis. Of these seven patients, six had AIHA with warm-reacting antibodies. The overall survival of patients with AIHA/NHL and the cohort was 44% and 76%, respectively; P = 0.006. The median survival for the patients who developed AIHA was 22.5 months and for the cohort > 32 months. Figure 2 depicts Kaplan-Meier estimate of survival for both groups (P < 0.0001). The process of rearrangement of the immunoglobulin (Ig) and T-cell receptor gene segments in the DNA of precursor lymphocytes not only allows the formation of large number of complete genes, but also creates the potential for the generation of autoreactive lymphocytes on a daily basis. Failure to eliminate these autoreactive cells or the breakdown in the mechanisms that prevent their expansion may lead to several autoimmune manifestations. Therefore, it is not surprising that patients with tumors of the immune system such as B-or T-cell NHL are at risk of developing antibodies against hematopoietic cells or other tissues [7, 8, 14] . Although similar phenomena have been described in patients with solid tumors, attempts to clarify their pathogenic mechanisms have concentrated mainly on patients with CD5+ or mature B-cell malignancies [15] [16] [17] . For example, Kipps et al. demonstrated the presence of autoantibodies associated cross-reactive idiotypes (CRIs) in patients with CD5+ B-cell chronic lymphocytic leukemia indicating a bias in the use of certain IgV genes that have not undergone significant diversification from germline DNA [18] . In contrast, Chapman et al. showed that somatic mutations and intraclonal diversity are frequently encountered in the IgV genes expressed by mature B-cell NHL [11] Similarly, replacement mutations in the third complimentary determining region (CDR 3 ) can be found in the IgV genes in patients with follicular NHL [19] . Finally, monoclonal IgM antibodies causing cold agglutinin disease in patients with underlying NHL have been characterized by the preferential use of the germline VH4-21 gene and the frequent somatic mutations in their light chain genes [20] .
At least in the case of follicular NHL, Burkitt's lymphoma and cold agglutinin disease, it appears that chronic stimulation by an antigen might have led, by unknown mechanism, to replacement mutations in the CDR of the light or heavy chain of the antibodies proliii li (t (Ji| s) Figure I . Kaplan-Meier analysis for time to complete response for the patients with NHL/AIHA (interrupted line) and the control (straight line). The difference between the 2 groups was not statistically significant (log-rank test; P = 0.167). Figure 2 . Kaplan-Meier estimate of survival for the patients with NHL/AIHA (interrupted line) and the cohort (straight line). The difference between the 2 groups was statistically significant (log-rank test; P < 0.0001).
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duced in association with these tumors [5, 16, 21] . The antigen may influence the formation of autoreactive lymphocytes in the thymus or bone marrow (Figure 3) . Failure of the immune system to eliminate these cells may lead to their expansion. In the majority of individuals, these autoreactive clones are subsequently inactivated or deleted from the immune repertoire by intact apoptotic mechanisms, while in some predisposed persons few of these cells remain to proliferate slowly in peripheral lymphoid organs. At a second phase, certain genetic factors such as dysregulation of BCL-2 or C-myc genes in patients with follicular center or Burkitt's lymphoma, respectively, may cause activation of the dormant cells. A third step in this process of autoantibody production may be the result of defects in the Fas/Fasligand interaction or in the B-/T-cell co-stimulatory pathways leading to expansion of a malignant T-cell clone that may influence a B-cell subpopulation to produce antibodies against RBCs [22, 23] . Similarly, the lack of surveillance exerted by Tsuppresser cells and the excessive production of certain cytokines combined by dysregulation in the apoptotic pathways could result in the formation of malignant B cell-producing antibodies against hematopoietic cells [25] . It is more than likely that other events take place before the final step of lymphogenesis/autoantibody production. The nature of these events, especially on cellular and molecular level remains to be clarified. Whether chronic antigen stimulation is required throughout this process is also unknown. In this study, AIHA was observed in 3% of patients with NHL evaluated during the study period; a figure similar to that reported by Gronbaek et al. [7] . Despite this favorable comparison, the cited frequency should be approached with some caution since patients with SLL and AILD were excluded from the current study. The overrepresentation of T-cell-derived NHL in this study is in accordance to what has been reported by other investigators in the field who described increased occurrence of autoimmune phenomena including AIHA in these patients [25, 26] . However, it is difficult to make meaningful comparison among the few available studies, since the pattern of referral to certain centers or bias in the selection of patients might have influenced the results. Nevertheless, the preponderance of T cell histology in this and other series remains an intriguing finding and may shed some light, not only on the mechanisms leading to AIHA, but also on the behavior of these tumors. Similarly, the significant association between AIHA and paraproteinemia noted in this study may be an indicative of the strong immune background of certain subsets of NHL. It is well known that AIHA is more likely to be associated with female gender [1] . According to the results of our study, this association remains valid in patients with NHL and AIHA.
Perhaps the most important finding of this study is the significantly lower survival of patients with NHL/ AIHA. Although the small sample size and heterogeneity of patients with AIHA might have affected the comparison of survival between the two groups, the results demonstrate that at least there was compromise of the course and outcome of patients with NHL who develop AIHA either prior or during the course of their illness. Since most of the characteristics between the cohort and the patients with AIHA are comparable in this study (Table 3) , one may speculate that the T-cell phenotype or the presence of paraproteinemia have conferred this adverse impact on the survival of these patients. It is also possible that immune hemolysis is a clinical manifestation of a greater degree of inherent pathobiologic derangement of the underlying NHL. On the other hand, in a similar fashion to CLL, the response of AIHA to treatment seems to be, at least in some patients, independent of the response of NHL. This is illustrated in the difference between time to CR of NHL and that for AIHA noted in this study. It is worthwhile mentioning that six of the patients with AIHA in this study had reticulocyte count < 2% at the time of diagnosis. This inappropriate response is likely caused by bone marrow involvement with lymphoma in these patients.
It is well known that cold agglutinin disease is more difficult to control than AIHA due to warm-reacting antibodies. This was demonstrated by the fact that 13 of the 14 patients who achieved response and 6 of the 7 patients who were alive at the conclusion of this analysis had warm hemolytic anemia. Another factor that affected the durability of response was the number of days needed to reach this response. The reason for this strong correlation between the time to achieve response and durability of response is unclear, but could be a result of the small sample size rather than the effect of time to CR of the underlying NHL, since one can easily observe the variability of time to CR for NHL in these six patients (Table 4) . It is worthwhile addressing that in six of the seven patients who remained alive (patients 3, 5, 7, 8, 13 and 16), resolution of AIHA was achieved in < 9 days.
In conclusion, AIHA remains a relatively uncommon occurrence in patients with NHL. The appearance of this complication seems to be independent of the stage of disease and therefore, factors other than those related to tumor bulkiness or growth fraction are likely to account for the poor prognosis of patients with NHL/ AIHA. The impact of this finding on the recommendations that can be offered based on this study is twofold. First, consideration should be given for the inclusion of immunomodulators such as cyclosporine or other agents in the treatment regimens of patients with NHL who develop AIHA with emphasis on achieving rapid resolution of the hemolytic process. Second, AIHA should be included in the risk-stratification of patients with NHL as an adverse prognostic sign. To better address these and other issues relevant to AIHA in patients with NHL, large-scale prospective trials are required.
